Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 32Unknown 4Withdrawn 3Terminated 2Recruiting 2Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 1Crohn Disease 1Arthritis, Rheumatoid 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Adalimumab × Clear all
NCT04655807 2025-04-27

DUET

Janssen Research & Development, LLC

Phase 2 Withdrawn

Crohn Disease

NCT02516774 2016-01-26

TAM-RT

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1 Withdrawn
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT00724672 2015-06-01

A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)

Merck Sharp & Dohme LLC

Withdrawn

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡